Biomerica Ownership
| BMRA Stock | USD 0.39 0.07 21.88% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 17 M | Current Value 17 M | Avarage Shares Outstanding 9.5 M | Quarterly Volatility 3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Biomerica |
Biomerica Stock Ownership Analysis
About 13.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.23. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biomerica recorded a loss per share of 0.37. The entity had not issued any dividends in recent years. The firm had 1:2 split on the 14th of November 1994. Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection andor treatment of medical conditions and diseases worldwide. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California. Biomerica operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 64 people. For more info on Biomerica please contact Zackary Irani at (949) 645-2111 or go to https://www.biomerica.com.Besides selling stocks to institutional investors, Biomerica also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Biomerica's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Biomerica's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Biomerica Quarterly Liabilities And Stockholders Equity |
|
About 7.0% of Biomerica are currently held by insiders. Unlike Biomerica's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Biomerica's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Biomerica's insider trades
Biomerica Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biomerica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomerica backward and forwards among themselves. Biomerica's institutional investor refers to the entity that pools money to purchase Biomerica's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Heritage Investors Management Corp | 2024-09-30 | 21 K | Northern Trust Corp | 2024-09-30 | 20.7 K | Penn Capital Management Company Llc | 2024-09-30 | 20.6 K | Two Sigma Securities, Llc | 2024-09-30 | 16.9 K | Raymond James Finl Svs Advisors, Inc. | 2024-09-30 | 14.5 K | Hollencrest Securities, Llc | 2024-09-30 | 11.6 K | Tower Research Capital Llc | 2024-09-30 | 3.9 K | Atlantic Trust Group, Llc | 2024-06-30 | 2.6 K | Bank Of America Corp | 2024-06-30 | 1.5 K | Granahan Investment Management Inc.. | 2024-09-30 | 527.5 K | Acadian Asset Management Llc | 2024-09-30 | 225.4 K |
Biomerica Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomerica insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomerica's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biomerica insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Allen Barbieri over three months ago Acquisition by Allen Barbieri of 1538 shares of Biomerica at 2.94 subject to Rule 16b-3 | ||
Allen Barbieri over three months ago Insider Trading | ||
Steven Sloan over six months ago Acquisition by Steven Sloan of 25000 shares of Biomerica at 6.36 subject to Rule 16b-3 | ||
Mark Sirgo over a year ago Acquisition by Mark Sirgo of 25000 shares of Biomerica subject to Rule 16b-3 |
Biomerica Outstanding Bonds
Biomerica issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biomerica uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biomerica bonds can be classified according to their maturity, which is the date when Biomerica has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BIOGEN INC 52 Corp BondUS09062XAD57 | View | |
| BIOGEN INC 405 Corp BondUS09062XAF06 | View | |
| BIOGEN INC Corp BondUS09062XAG88 | View | |
| BIOGEN INC Corp BondUS09062XAH61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| BIIB 325 15 FEB 51 Corp BondUS09062XAK90 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biomerica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomerica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomerica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomerica Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomerica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomerica. If investors know Biomerica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomerica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 0.327 | Quarterly Revenue Growth 0.055 | Return On Assets (0.39) | Return On Equity (0.76) |
The market value of Biomerica is measured differently than its book value, which is the value of Biomerica that is recorded on the company's balance sheet. Investors also form their own opinion of Biomerica's value that differs from its market value or its book value, called intrinsic value, which is Biomerica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomerica's market value can be influenced by many factors that don't directly affect Biomerica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomerica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomerica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomerica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.